Short Interest in Portage Biotech Inc. (NASDAQ:PRTG) Expands By 175.0%

Portage Biotech Inc. (NASDAQ:PRTG) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 26,400 shares, an increase of 175.0% from the December 31st total of 9,600 shares. Approximately 6.0% of the company’s stock are short sold. Based on an average daily trading volume, of 639,500 shares, the days-to-cover ratio is presently 0.0 days.

Portage Biotech Stock Performance

PRTG traded down $0.15 during trading on Friday, hitting $4.41. The stock had a trading volume of 753,853 shares, compared to its average volume of 58,302. The company has a market capitalization of $4.63 million, a PE ratio of -0.11 and a beta of 1.33. Portage Biotech has a twelve month low of $2.10 and a twelve month high of $23.01. The stock has a 50 day simple moving average of $4.65 and a two-hundred day simple moving average of $4.75.

Portage Biotech (NASDAQ:PRTG) last announced its earnings results on Tuesday, November 26th. The company reported ($1.26) earnings per share for the quarter. On average, equities research analysts anticipate that Portage Biotech will post -13 EPS for the current year.

Institutional Investors Weigh In On Portage Biotech

An institutional investor recently bought a new position in Portage Biotech stock. Virtu Financial LLC acquired a new position in shares of Portage Biotech Inc. (NASDAQ:PRTG) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned 1.04% of Portage Biotech at the end of the most recent quarter. Institutional investors own 13.36% of the company’s stock.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.